Advertisement

Volume 3, Issue 17

 

Cover Image

Cover Figure: T cells attacking cancer cells. Meletios Verras | Dreamstime.com.

WASHINGTON, D.C., September 10, 2019 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

In this issue's Blood Advances Talk, Lucy A. Godley discusses the topic of inherited predisposition to myeloid malignancies. We hope you find this informative and of interest.

 

 

Complications from sickle cell disease include hemolysis, vaso-occlusion, and ischemia. Superoxide dismutase 2 (SOD2) has been shown to modulate the severity of the disease. In a review, Straub and colleagues detailed the role of SOD2 in the pathophysiology of sickle cell disease as well as strategies to enhance expression and impact complications of the disorder.

 

 

The use of haploidentical donors has become an important addition to the donor pool for patients who could benefit from an allogeneic hematopoietic cell transplant. In a Systematic Review, Rashidi and colleagues evaluated a comparison of outcomes with matched sibling donors to haploidentical donors and reach important clinical findings.

 

 

Allogeneic transplantation has proven to be a curative approach to the treatment of patients with β-thalassemia major. However, most published studies have included a relatively small numbers of patients. Eapen and colleagues performed an international survey of 1110 patients. The survey helps to define outcomes in many different clinically relevant scenarios that form the basis of validating this approach and suggests areas for future improvement.

Cytotoxic T cells (CTLs) have shown great promise for the treatment of patients with infectious and malignant disorders. Third-party CTLs represent an off-the-shelf product with demonstrated efficacy. In the report by Tzannou and colleagues, a bank of only 8 donors can provide cells for a diverse population.

 

 

In a report from Johns Hopkins University, Jones and colleagues report on older patients (>70 years of age) with hematological malignancies treated with transplantation utilizing haploidentical donors, demonstrating the feasibility of treating such patients with acceptable risks and favorable outcomes. They demonstrated the feasibility of treating such patients with acceptable risks and favorable outcomes. However, the challenges of treating patients in this age range were also evident.

 

 


 

 

 

Blood Advances is the open-access journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.